Guozhang Xu

848 total citations
34 papers, 665 citations indexed

About

Guozhang Xu is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Guozhang Xu has authored 34 papers receiving a total of 665 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 9 papers in Organic Chemistry and 8 papers in Oncology. Recurrent topics in Guozhang Xu's work include Diabetes Treatment and Management (6 papers), HER2/EGFR in Cancer Research (4 papers) and HIV/AIDS drug development and treatment (4 papers). Guozhang Xu is often cited by papers focused on Diabetes Treatment and Management (6 papers), HER2/EGFR in Cancer Research (4 papers) and HIV/AIDS drug development and treatment (4 papers). Guozhang Xu collaborates with scholars based in United States, China and Belgium. Guozhang Xu's co-authors include Lawrence M. Sayre, Yahu A. Liu, Quan Yuan, Weihan Zhang, Stuart L. Emanuel, Peter J. Connolly, Steven A. Middleton, Mary Adams, Jim A. Turpin and Robert W. Buckheit and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and The Journal of Organic Chemistry.

In The Last Decade

Guozhang Xu

33 papers receiving 659 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Guozhang Xu United States 16 296 269 104 82 76 34 665
Yih Ho Taiwan 19 82 0.3× 478 1.8× 144 1.4× 118 1.4× 54 0.7× 55 951
Mukesh Chourasia India 14 192 0.6× 323 1.2× 87 0.8× 20 0.2× 40 0.5× 27 784
Henrietta Dehmlow Switzerland 15 197 0.7× 621 2.3× 121 1.2× 61 0.7× 51 0.7× 21 969
Joyce A. Boucheron United States 17 203 0.7× 505 1.9× 82 0.8× 62 0.8× 15 0.2× 24 954
Malek Zihlif Jordan 15 120 0.4× 297 1.1× 125 1.2× 67 0.8× 24 0.3× 78 742
Susana D. Lucas Portugal 18 273 0.9× 345 1.3× 107 1.0× 37 0.5× 17 0.2× 40 763
Annalisa Maruca Italy 14 150 0.5× 258 1.0× 47 0.5× 36 0.4× 37 0.5× 26 499
Sumiko Hyuga Japan 17 166 0.6× 564 2.1× 102 1.0× 76 0.9× 31 0.4× 54 982
Maria de Jesus Perry Portugal 16 243 0.8× 212 0.8× 48 0.5× 108 1.3× 19 0.3× 34 734
Pat Wheelan United States 17 272 0.9× 402 1.5× 134 1.3× 58 0.7× 30 0.4× 39 863

Countries citing papers authored by Guozhang Xu

Since Specialization
Citations

This map shows the geographic impact of Guozhang Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guozhang Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guozhang Xu more than expected).

Fields of papers citing papers by Guozhang Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guozhang Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guozhang Xu. The network helps show where Guozhang Xu may publish in the future.

Co-authorship network of co-authors of Guozhang Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Guozhang Xu. A scholar is included among the top collaborators of Guozhang Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guozhang Xu. Guozhang Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Qi, Jenson, et al.. (2021). GRK Inhibition Potentiates Glucagon-Like Peptide-1 Action. Frontiers in Endocrinology. 12. 4 indexed citations
2.
Xu, Guozhang, Fuyong Du, Gee‐Hong Kuo, et al.. (2020). 5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors. Bioorganic & Medicinal Chemistry Letters. 30(17). 127387–127387. 10 indexed citations
3.
Xu, Guozhang, Michael D. Gaul, Zhi‐Jie Liu, et al.. (2020). Hit-to-lead optimization and discovery of a potent, and orally bioavailable G protein coupled receptor kinase 2 (GRK2) inhibitor. Bioorganic & Medicinal Chemistry Letters. 30(23). 127602–127602. 3 indexed citations
4.
Song, Fengbin, Guozhang Xu, Michael D. Gaul, et al.. (2019). Design, synthesis and structure activity relationships of indazole and indole derivatives as potent glucagon receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 29(15). 1974–1980. 18 indexed citations
5.
Xu, Guozhang, Michael D. Gaul, Fengbin Song, et al.. (2019). Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetes. Bioorganic & Medicinal Chemistry Letters. 29(20). 126668–126668. 3 indexed citations
6.
Kuo, Gee‐Hong, Micheal D. Gaul, Yin Liang, et al.. (2018). Synthesis and biological evaluation of benzocyclobutane-C-glycosides as potent and orally active SGLT1/SGLT2 dual inhibitors. Bioorganic & Medicinal Chemistry Letters. 28(7). 1182–1187. 29 indexed citations
7.
Patch, Raymond J., Hui Huang, Sharmila Patel, et al.. (2017). Indazole-based ligands for estrogen-related receptor α as potential anti-diabetic agents. European Journal of Medicinal Chemistry. 138. 830–853. 30 indexed citations
8.
Xu, Guozhang. (2012). Economic burden estimation for pandemic hand foot and mouth disease in Ningbo City,2011. 2 indexed citations
9.
Xu, Guozhang. (2008). Maternal-infant pairs comparative study on the change of maternal transferred measles antibody level in infants. Chinese Journal of Public Health. 3 indexed citations
10.
Xu, Guozhang, Terry V. Hughes, Peter J. Connolly, et al.. (2008). Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases. Bioorganic & Medicinal Chemistry Letters. 18(12). 3495–3499. 48 indexed citations
11.
Hughes, Terry V., Guozhang Xu, Steven K. Wetter, et al.. (2008). A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: Design, synthesis, and biological activity. Bioorganic & Medicinal Chemistry Letters. 18(17). 4896–4899. 24 indexed citations
12.
Kreutter, K. D., Tianbao Lu, Lily Lee, et al.. (2008). Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif. Bioorganic & Medicinal Chemistry Letters. 18(9). 2865–2870. 24 indexed citations
13.
Gaul, Micheal D., et al.. (2007). 4-Amino-6-piperazin-1-yl-pyrimidine-5-carbaldehyde oximes as potent FLT-3 inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(17). 4861–4865. 15 indexed citations
14.
Huang, Shenlin, Ronghua Li, Peter J. Connolly, et al.. (2006). Synthesis and biological study of 4-aminopyrimidine-5-carboxaldehyde oximes as antiproliferative VEGFR-2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(23). 6063–6066. 21 indexed citations
15.
Xu, Guozhang, et al.. (2002). Synthesis of alkenyldiarylmethane (ADAM) non-Nucleoside HIV-1 reverse transcriptase inhibitors with non-Identical aromatic rings. Bioorganic & Medicinal Chemistry. 10(2). 283–290. 17 indexed citations
16.
17.
Xu, Guozhang, Tracy L. Hartman, Karen Watson, et al.. (2002). Synthesis of substituted diarylmethylenepiperidines (DAMPs), a novel class of anti-HIV agents. Bioorganic & Medicinal Chemistry. 10(8). 2807–2816. 11 indexed citations
18.
Xu, Guozhang. (2001). Studies of Risk Factors on Toxoplasma Gondii Infection in Maternal Women and Newborn Infants. China Public Health. 1 indexed citations
19.
20.
Xu, Guozhang, et al.. (2001). Solid-Phase Synthesis of the Alkenyldiarylmethane (ADAM) Series of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. The Journal of Organic Chemistry. 66(18). 5958–5964. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yih Ho Breakdown of academic impact, for papers by Mukesh Chourasia Breakdown of academic impact, for papers by Henrietta Dehmlow Breakdown of academic impact, for papers by Joyce A. Boucheron Breakdown of academic impact, for papers by Malek Zihlif Breakdown of academic impact, for papers by Susana D. Lucas Breakdown of academic impact, for papers by Annalisa Maruca Breakdown of academic impact, for papers by Sumiko Hyuga Breakdown of academic impact, for papers by Maria de Jesus Perry Breakdown of academic impact, for papers by Pat Wheelan
Rankless by CCL
2026